Virosome studied by MedImmune
By Dylan Bushell-Embling
Friday, 18 July, 2008
Friday, 18 July, 2008
Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.
The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.
MedImmune is a member of the AstraZeneca group.
Related News
Cannabis use may double risk of cardiovascular disease death
Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...
Space conditions can lead to periodontitis, scientists say
Living in zero gravity can lead to periodontitis — a serious condition where the gums...
Personalised brain stimulation helps treat those with depression
By tailoring transcranial magnetic stimulation to each person's unique brain structure,...
